Fifteen-year follow-up study of Rebif patients published

A board to discuss the Multiple Sclerosis modifying drug Rebif

Fifteen-year follow-up study of Rebif patients published

Postby MSUK » Tue Oct 13, 2015 3:29 am

EMD Serono, the American biopharmaceutical business of Merck KGaA, Darmstadt, Germany, has announced that the Journal of Neurology, Neurosurgery and Psychiatry (JNNP) has published 15-year follow-up data for Rebif, the company's high-dose, high-frequency beta interferon for relapsing-remitting multiple sclerosis (RRMS), from the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) trial... Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2815
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Re: Fifteen-year follow-up study of Rebif patients published

Postby chenman » Sun Nov 22, 2015 7:21 am

I have tried, cannot find this article on the MSUK-pages...

After searching elsewhere I found the original:
http://jnnp.bmj.com/content/early/2015/ ... 4.full.pdf

I went to the end of that paper, found this:
"Competing interests
All authors have completed the Unified Competing Interests form at http://icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: LK’s
Institution (University Hospital Basel) has
received and used exclusively for research support: steering committee, advisory
board and consultancy fees from Actelion, Addex, Bayer HealthCare, Biogen, Biotica,
Genzyme, Lilly, Merck, Mitsubishi, Novartis, Ono Pharma, Pfizer, Receptos, Sanofi-Aventis, Santhera, Siemens, Teva, UCB and Xenoport; speaker fees from Bayer HealthCare, Biogen, Merck, Novartis, Sanofi-Aventis and Teva; support of educational activities from Bayer HealthCare, Biogen, CSL Behring, Genzyme, Merck, Novartis, Sanofiand Teva; royalties from Neurostatus Systems GmbH; and grants from Bayer HealthCare, Biogen, Merck, Novartis, Roche, the Swiss Multiple Sclerosis
Society, the Swiss National Research Foundation, the European Union and Roche Research Foundations. JK has received research support from Bayer, Biogen Idec, Novartis and Roche. JM has received consultation/lecture fees and congress fees from Bayer, Biogen Idec, Merck Serono and Sanofi-Aventis; consultation fees from Almirall; and congress fees from Novartis and Orion. MK has received consultation/lecture fees and congress fees from Bayer, Biogen Idec, Merck Serono and
Sanofi-Aventis; congress fees from Novartis; and institutional research support from
Merck Serono, Sanofi-Aventis and Biogen Idec. EVdC, PC, LL, FC-S and DI were
salaried employees of Merck Serono SA Geneva, Switzerland, at the time of the
study
. BMJU has received consultation fees from Novartis, Merck Serono, Biogen
Idec, Synthon and Danone Research

I declined from investing time to study this masterpiece of contemporary neurological "research"... PR...

MSUK wrote:EMD Serono, the American biopharmaceutical business of Merck KGaA, Darmstadt, Germany, has announced that the Journal of Neurology, Neurosurgery and Psychiatry (JNNP) has published 15-year follow-up data for Rebif, the company's high-dose, high-frequency beta interferon for relapsing-remitting multiple sclerosis (RRMS), from the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) trial... Read more - http://www.ms-uk.org/MSnews
chenman
Family Member
 
Posts: 32
Joined: Wed Nov 18, 2015 12:29 pm


Return to Rebif

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service